Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Cyprotex Plc

2 Nov 2016 10:09

RNS Number : 1336O
Nplus1 Singer Capital Markets Ltd
02 November 2016
 

FORM 8.5 (EPT/RI)

 

This disclosure replaces RNS 4994N which was disclosed in error.

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Cyprotex Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Cyprotex Plc

 

(d) Date dealing undertaken:

01 November 2016

 

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

If YES, specify which:

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 1P

 

Purchase

 

11653

 

 

156.64p

 

156.64p

 

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

02 November 2016

Contact name:

Damian Fernandez

Telephone number:

020 7496 3093

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBTBMTMBMMBFF
Date   Source Headline
21st Mar 20137:00 amRNSFinal Results
15th Mar 20137:00 amRNSNotice of Results
26th Feb 201312:05 pmRNSHolding(s) in Company
26th Feb 201312:05 pmRNSHolding(s) in Company
14th Feb 20137:00 amRNSLaunch of new cardiotoxicity service-eCiphrCardio
11th Jan 20137:00 amRNSIssue of Equity
13th Dec 20127:00 amRNSTrading Statement
30th Oct 20127:00 amRNSRe Agreement with Pfizer
29th Oct 20127:00 amRNSChange of NOMAD Name
16th Oct 20127:00 amRNSLicensing Agreement with Sigma Life Science
20th Sep 20127:00 amRNSCellCiphr Premier Launch
6th Sep 20127:00 amRNSHalf Yearly Report
6th Sep 20127:00 amRNSJoint Service Offering
4th Sep 20127:00 amRNSNotice of Results
4th Sep 20127:00 amRNSBoard Change
2nd Aug 20127:00 amRNSUpdated Regulatory Guidance Booklet
18th Jul 20121:49 pmRNSResult of AGM
21st Jun 20127:00 amRNSAlliance with Sirius Analytical
3rd May 20127:00 amRNSProduct Launch
22nd Mar 20127:00 amRNSFinal Results
12th Jan 20127:00 amRNSPre-Closed Trading Update
16th Dec 20117:00 amRNSSygnature Discovery and Cyprotex Extend Alliance
9th Nov 20117:00 amRNSProduct Upgrade
7th Nov 20117:00 amRNSExpansion of US Facility
29th Sep 20117:00 amRNSBoard Change
25th Aug 20117:00 amRNSHalf Yearly Report
8th Jul 20117:00 amRNSRe Agreement
30th Jun 20117:00 amRNSAGM Statement
23rd Mar 20117:00 amRNSFinal Results
11th Mar 201112:34 pmRNSRevised date for Results
1st Mar 201112:50 pmRNSNotice of Results
24th Dec 20107:00 amRNSTrading Statement
8th Nov 20104:53 pmRNSDirector/PDMR Shareholding
1st Nov 20107:00 amRNSAppointment of New Non-Executive Director
19th Oct 201010:07 amRNSProduct Update
12th Oct 20109:37 amRNSLaunches new transporter assay for BCRP
1st Oct 20107:00 amRNSCyprotex officially open new toxicology laboratory
16th Sep 20107:00 amRNSCyprotex and TB Alliance form collaboration
1st Sep 20107:00 amRNSProvides free online access to Cloe Knowledge
20th Aug 20107:00 amRNSCyprotex Adds In Vitro Toxicology Services
19th Aug 20109:30 amRNSHolding(s) in Company
18th Aug 20103:30 pmRNSHolding(s) in Company
18th Aug 20103:18 pmRNSHolding(s) in Company
18th Aug 20102:16 pmRNSDirector/PDMR Shareholding - amendment
18th Aug 20107:00 amRNSDirector/PDMR Shareholding
12th Aug 20107:00 amRNSHalf Yearly Report
6th Aug 20107:00 amRNSAcquisition of Apredica
14th Jul 20103:05 pmRNSResult of AGM
14th Jul 20107:00 amRNSAGM Statement
2nd Jul 20107:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.